Navigation Links
Watson Pharmaceuticals Announces New Research Showing RAPAFLO(R) (silodosin) Improves Outcomes for Chronic Prostatitis/Chronic Pelvic Pain Syndrome
Date:5/17/2011

ha (1B) receptors that cause smooth muscle in peripheral vessels is significantly lower, which may minimize orthostatic hypotension.

The most common drug-related side effect was retrograde ejaculation, or orgasm with reduced semen, which is reversible upon discontinuation of the product. The second most commonly-reported adverse event was dizziness. The incidence of treatment-related dizziness was low and only slightly higher among patients treated with RAPAFLO(R) than placebo-treated patients.

Previously presented data included information that in clinical trials RAPAFLO(R) was administered concomitantly with a single dose of medications for erectile dysfunction in healthy male subjects (N=24) and that there were no reported events of symptomatic orthostatis or dizziness. RAPAFLO(R) demonstrated no meaningful electro cardiac effects during Phase 3 trials and during thorough QTc testing as required for new chemical entities by the FDA.

RAPAFLO(R) was originally developed by Kissei Pharmaceutical Co., Ltd. in Japan, where RAPAFLO(R) is the BPH market leader, and is licensed to Watson for the U.S., Canada and Mexico markets.

Important Safety Information

RAPAFLO(R) is contraindicated in patients with severe renal impairment (CCr <30 mL/min), severe hepatic impairment (Child-Pugh score >/=10), and with use of strong CYP3A4 inhibitors. Postural hypotension with or without symptoms (eg, dizziness) may develop when beginning treatment with RAPAFLO(R). As with all alpha-blockers, there is a potential for syncope. Patients should be warned of the possible occurrences of such events and should avoid situations where injury could result. RAPAFLO(R) should be used with caution in patients with moderate renal impairment. Patients should be assessed to rule out the presence of prostate cancer prior to starting treatment with RAPAFLO(R). Patients planning cataract surgery should inform their ophthalmologist that they are taking RAPAF
'/>"/>

SOURCE Watson Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Watson Confirms Renvela® Patent Challenge
2. Delaware Court Rules That Watson Does Not Infringe Patent Related to Generic Version of Concerta(R) and Declares Patent Invalid
3. Watsons GELNIQUE(TM) (oxybutynin chloride) Gel 10% Approved by FDA for the Treatment of Overactive Bladder
4. Auxilium Pharmaceuticals, Inc. Announces First Quarter 2011 Financial Results and Operational Highlights
5. Inovio Pharmaceuticals Reports Long-Term Immune Responses from Therapeutic Cervical Dysplasia and Cancer DNA Vaccine
6. Vanda Pharmaceuticals Reports First Quarter 2011 Results
7. MAP Pharmaceuticals Reports First Quarter of 2011 Financial Results
8. Anadys Pharmaceuticals to Report First Quarter 2011 Financial Results
9. Keryx Biopharmaceuticals, Inc. Announces First Quarter 2011 Financial Results
10. Keryx Biopharmaceuticals, Inc. To Host Conference Call on First Quarter 2011 Financial Results
11. Keryx Biopharmaceuticals Announces Positive Final Data from Zerenex™ Short-Term Phase 3 Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... Francisco, CA (PRWEB) July 24, 2014 ... http://www.draperuniversity.com , is proud to announce that ... from 17 different countries will converge on the ... Valley for an intensive, experiential program focused on ... The highly selective school, currently running its sixth ...
(Date:7/24/2014)... (PRWEB) July 24, 2014 The ... of molecular diagnostic test results. It also enables ... for the validation and reporting of high profile ... diagnostics is a rapidly growing area of biotechnology ... genetic predisposition, cancer, and companion diagnostics in personalized ...
(Date:7/23/2014)... strides in saving China,s endangered national treasure, the giant ... panda reserves that have been established and three large ... remain in the wild. , Breeding programs in ... by improving genetic diversity, avoid inbreeding and ultimately, introduce ... high-profile programs doing so far? , In a new ...
(Date:7/23/2014)... 23, 2014  AuraSense Therapeutics, the pioneer in developing ... regulatory and immunotherapeutic agents, announced today that ... Therapeutics, executive leadership team as chief financial ... to joining AuraSense Therapeutics, Mr. Snyder was ... of Cellular Dynamics International Inc., where he ...
Breaking Biology Technology:Summer Entrepreneurship Program Kicked Off by Draper University in Silicon Valley 2Summer Entrepreneurship Program Kicked Off by Draper University in Silicon Valley 3New DNA-barcode Patent Virtually Eliminates False Test Results and Sample Mix-up 2AuraSense Therapeutics Appoints Biotechnology Veteran David S. Snyder as Chief Financial Officer 2
... and development will dominate a surge in demand for ... study released this week by a New York consulting ... Lux Research , also projected that sales of ... years. , ,"Interest in nanotechnology focuses on remarkable applications ...
... Fiserv, Inc. and CUNA Mutual Group ... of CUNA Mutual's payment protection products during ... solutions offered by Fiserv business units. The ... protection products, which include credit life, credit disability and ...
... Source: Visions 2005 Madison, Wis. - ... of postage stamp size videos of staid corporate meetings, running ... of the seafloor? , ,Audiences will have the opportunity to ... The Sea" event, hosted locally by the UW-Madison Division ...
Cached Biology Technology:Corporate clients will dominate surge in nanotech tool demand, study projects 2Corporate clients will dominate surge in nanotech tool demand, study projects 3Deep sea event will put spotlight on Internet 2 capabilities 2
(Date:7/24/2014)... sake brewery has its own microbial terroir, meaning the ... those found in the product, creating the final flavor ... journal Applied and Environmental Microbiology . This is ... of a sake brewery. , Many sake makers ... David A. Mills of the University of California, Davis, ...
(Date:7/24/2014)... similar counterparts in humans, affect the connections between nerve ... the hippocampus, an area of the brain that plays ... of memories. The results of the study have been ... function depends on the active communication between nerve cells, ... together into a dense network where they constantly relay ...
(Date:7/24/2014)... researchers and patients have hoped that embryonic stem cells ... bodycould provide insight into numerous diseases perhaps even be ... by the inability to transfer research and tools from ... because human ESCs are "primed" and slightly less plastic ... Powell, and Haoyi Wang, who are scientists in the ...
Breaking Biology News(10 mins):The microbes make the sake brewery 2A protein couple controls flow of information into the brain's memory center 2A protein couple controls flow of information into the brain's memory center 3A protein couple controls flow of information into the brain's memory center 4Whitehead Institute researchers create 'na&#239;ve' pluripotent human embryonic stem cells 2
... HOBOKEN, N.J. Stevens Institute of Technology,s Center for ... Warning System (EWS) for Inundations in the Dominican Republic. ... DR,s EWS and providing the most up-to-date equipment to ... on the island. , The genesis of the EWS ...
... Wistar Institute and their colleagues have identified, for the first ... of RNA that play a vital role in gene expression ... way to the development of a new generation of cancer ... that blocks the pathway of a particular miRNA, called miR-21, ...
... September 23, 2008 Researchers at Sentara ... explore the safety and effectiveness of stents to open ... Pulmonary Disease (COPD). The EASE (Exhale Airway ... investigational technique without surgery to create new pathways to ...
Cached Biology News:Stevens strengthens Dominican Republic's Early Warning System for Inundations 2Stevens strengthens Dominican Republic's Early Warning System for Inundations 3Scientists identify novel inhibitor of human microRNA 2Scientists identify novel inhibitor of human microRNA 3Sentara begins international trial -- open at only 24 US locations 2
Human VASA Biotinylated Affinity Purified PAb...
[14C]Polyethylene glycol 4000, 9.25 MBq, 250 uCi. Aqueous solution containing 3% ethanol, sterilized. 370-740 MBq/g, 10-20 mCi/g.1.85 MBq/ml, 50 uCi/ml. Category: Radiochemicals &Radiation Safety, ...
... kit for all types of yeast two-hybrid studies, including ... Choice of two bait vectors for ... Triple reporter strain ... Complete set of controls: pLexA-p53, ...
Mouse Limitin MAb (Clone 183727)...
Biology Products: